{"id":6687,"date":"2025-02-03T17:02:02","date_gmt":"2025-02-03T17:02:02","guid":{"rendered":"https:\/\/stoxpo.com\/?p=6687"},"modified":"2025-02-03T17:02:03","modified_gmt":"2025-02-03T17:02:03","slug":"hcw-biologics-gains-fda-clearance-for-first-in-human-trial-of-novel-alopecia-areata-treatment","status":"publish","type":"post","link":"https:\/\/stoxpo.com\/index.php\/2025\/02\/03\/hcw-biologics-gains-fda-clearance-for-first-in-human-trial-of-novel-alopecia-areata-treatment\/","title":{"rendered":"HCW Biologics Gains FDA Clearance for First-in-Human Trial of Novel Alopecia Areata Treatment"},"content":{"rendered":"\n

Phase 1 Trial of HCW9302 Marks a Milestone in Autoimmune Disease Research<\/h4>\n\n\n\n

HCW Biologics (HCWB), a clinical-stage biopharmaceutical company specializing in innovative immunotherapies, has announced FDA clearance for its Investigational New Drug Application (IND) to begin a first-in-human Phase 1 clinical trial of HCW9302. This trial will evaluate the drug’s safety and efficacy in patients suffering from moderate-to-severe alopecia areata, an autoimmune disease characterized by sudden hair loss and a significant impact on psychological well-being.<\/p>\n\n\n\n

HCW9302 is a groundbreaking interleukin 2 (IL-2) fusion protein complex developed using HCW’s proprietary TOBI platform technology. It functions by binding to IL-2\u03b1\u03b2\u03b3 receptors, primarily found on regulatory T (Treg) cells, which helps activate and expand these cells to suppress harmful immune and inflammatory responses. This mechanism offers hope for patients who currently have no FDA-approved curative treatments for alopecia areata.<\/p>\n\n\n\n

Preclinical models have demonstrated HCW9302\u2019s efficacy in treating autoimmune diseases at well-tolerated doses, showing potential beyond alopecia areata. The injectable, subcutaneous approach aims to reduce inflammation while minimizing the risk of broad immunosuppression.<\/p>\n\n\n\n

Dr. Hing C. Wong, Founder and CEO of HCW Biologics, expressed enthusiasm about the FDA\u2019s decision, stating, \u201cThis clearance brings us one step closer to offering a transformative immunotherapeutic for autoimmune diseases. While alopecia areata is not life-threatening, its psychological toll is profound, and current treatments often carry severe side effects.\u201d<\/p>\n\n\n\n

The primary goal of the Phase 1 trial is to establish a safe and effective dose of HCW9302 that boosts Treg cell activity. Success in this phase could lead to expanded trials targeting other autoimmune and inflammatory conditions, including graft rejection, atherosclerosis, diabetes, and neurodegenerative diseases.<\/p>\n\n\n\n

Read original press release here<\/mark><\/a><\/p>\n\n\n\n

You might like this article:Trump\u2019s New Tariffs Spark Global Retaliation and Trade War Fears<\/mark><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Phase 1 Trial of HCW9302 Marks a Milestone in Autoimmune Disease Research HCW Biologics (HCWB), a clinical-stage biopharmaceutical company specializing in innovative immunotherapies, has announced FDA clearance for its Investigational New Drug Application (IND) to begin a first-in-human Phase 1 clinical trial of HCW9302. This trial will evaluate the drug’s safety and efficacy in patients […]<\/p>\n","protected":false},"author":2,"featured_media":1430,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","jnews-multi-image_gallery":[],"jnews_single_post":{"subtitle":"","format":"standard","video":"","gallery":"","source_name":"","source_url":"","via_name":"","via_url":"","override_template":"0","override":[{"template":"8","single_blog_custom":"","parallax":"1","fullscreen":"1","layout":"right-sidebar-narrow","sidebar":"author","second_sidebar":"single-right","sticky_sidebar":"1","share_position":"top","share_float_style":"share-monocrhome","show_share_counter":"0","show_view_counter":"0","show_featured":"1","show_post_meta":"1","show_post_author":"1","show_post_author_image":"0","show_post_date":"1","post_date_format":"default","post_date_format_custom":"Y\/m\/d","show_post_category":"1","show_post_reading_time":"1","post_reading_time_wpm":"300","show_zoom_button":"0","zoom_button_out_step":"2","zoom_button_in_step":"3","show_post_tag":"1","show_prev_next_post":"1","show_popup_post":"1","number_popup_post":"1","show_author_box":"0","show_post_related":"1","show_inline_post_related":"0"}],"override_image_size":"0","image_override":[{"single_post_thumbnail_size":"crop-500","single_post_gallery_size":"crop-500"}],"trending_post":"0","trending_post_position":"meta","trending_post_label":"Trending","sponsored_post":"0","sponsored_post_label":"Sponsored by","sponsored_post_name":"","sponsored_post_url":"","sponsored_post_logo_enable":"0","sponsored_post_logo":"","sponsored_post_desc":"","disable_ad":"0"},"jnews_primary_category":{"id":"","hide":""},"jnews_social_meta":{"fb_title":"","fb_description":"","fb_image":"","twitter_title":"","twitter_description":"","twitter_image":""},"jnews_override_counter":{"override_view_counter":"0","view_counter_number":"0","override_share_counter":"0","share_counter_number":"0","override_like_counter":"0","like_counter_number":"0","override_dislike_counter":"0","dislike_counter_number":"0"},"jnews_post_split":{"enable_post_split":"0","post_split":[{"template":"1","tag":"h2","numbering":"asc","mode":"normal","first":"0","enable_toc":"0","toc_type":"normal"}]}},"categories":[308,359],"tags":[419,421,416,418,417],"coauthors":[454],"_links":{"self":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/6687"}],"collection":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/comments?post=6687"}],"version-history":[{"count":1,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/6687\/revisions"}],"predecessor-version":[{"id":6688,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/6687\/revisions\/6688"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media\/1430"}],"wp:attachment":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media?parent=6687"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/categories?post=6687"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/tags?post=6687"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/coauthors?post=6687"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}